Biotech and drug stocks

Why Biohaven Stock Caught Fire This Week

Shares of the clinical-stage biopharma Biohaven (NYSE: BHVN) rocketed higher by 33.5% over the first four days of trading this week, according to data provided by S&P Global Market Intelligence. The big gain was sparked by the company's research and development day presentation held on Wednesday. Highlights from Biohaven's presentation include the unexpected Food and Drug Administration (FDA) regulatory filing for the experimental spinocerebellar ataxia type 3 drug troriluzole, status updates on its closely watched epilepsy program, and a clinical strategy overview for its newly acquired neuroinflammatory asset BHV-8000.

3 High-Quality Dividend Stocks Yielding 3% to Buy in June

Many high-quality dividend stocks currently yield around 3%, nearly double that of the S&P 500. American Tower's dividend yield is currently over 3%, a historically high rate for the data-infrastructure real estate investment trust (REIT). The company has an exceptional track record of paying dividends.

Novartis drug cuts recurrence risk by 25% in early-stage breast cancer

Novartis breast cancer drug Kisqali cut the risk of recurrence by a little more than 25% in a pivotal trial on women diagnosed at an early stage, positioning the Swiss drugmaker to win new patients and challenging strong rival Eli Lilly. The company on Friday said the relative risk reduction of cancer recurrence was 25.2% and that the results were broadly consistent regardless of patients' menopausal status or cancer progression status. The results were presented at the annual meeting of the American Society of Clinical Oncology in Chicago.Kisqali was used in the trial together with standard endocrine therapy to treat a type of cancer that grows in response to hormones and it was compared to endocrine therapy alone.

Lilly Highlights Verzenio® (abemaciclib) and Jaypirca™ (pirtobrutinib) Data at 2023 ASCO® Annual Meeting

Eli Lilly and Company (NYSE: LLY) today announced Verzenio® (abemaciclib; CDK4/6 inhibitor) and Jaypirca™ (pirtobrutinib; non-covalent (reversible) BTK inhibitor) data to be presented at the 2023 ASCO® Annual Meeting in Chicago, June 2 – 6, 2023. Presentations include new analyses from the Phase 3 monarchE trial of two years of Verzenio treatment in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), node-positive, high risk early breast canc

Novartis Kisqali® significantly reduced the risk of recurrence by 25% across a broad population of patients with early breast cancer; clinically meaningful benefit was consistent across subgroups

Kisqali is the first and only CDK4/6 inhibitor to demonstrate a consistent, clinically meaningful benefit across a broad population of patients with HR+/HER2- early breast cancer, regardless of disease stage, menopausal or nodal status1 Results were also consistent across all secondary endpoints, including distant disease-free survival and recurrence-free survival, with a trend for improved overall survival*1 The safety profile of Kisqali was favorable at 400 mg with low rates of symptomatic adv

Bayer (BAYRY) & Cedilla to Co-Develop Novel Cancer Therapies

Bayer (BAYRY) announces licensing agreement with Cedilla Therapeutics to jointly develop and commercialize the latter's selective protein complex inhibitors as novel cancer therapies.

Bristol-Myers Squibb Company (NYSE:BMY) is largely controlled by institutional shareholders who own 78% of the company

Key Insights Given the large stake in the stock by institutions, Bristol-Myers Squibb's stock price might be vulnerable...

Possible Bearish Signals With Amgen Insiders Disposing Stock \

Over the past year, many Amgen Inc. ( NASDAQ:AMGN ) insiders sold a significant stake in the company which may have...

BioNTech and OncoC4 Present Positive Phase 1/2 Data for Antibody Candidate BNT316/ONC-392 in Hard-to-Treat NSCLC at ASCO

BNT316/ONC-392 is a next-generation anti-CTLA-4 monoclonal antibody candidate jointly developed by BioNTech and OncoC4 as monotherapy or combination therapy in a range of solid tumor indications, including non-small cell lung cancer (NSCLC)Interim data of BNT316/ONC-392 from the ongoing Phase 1/2 trial to be presented at this year’s ASCO Annual Meeting demonstrate encouraging signs of clinical anti-tumor activity and a manageable safety profile in patients with metastatic, PD-(L)1-resistant NSCL

The area's largest life sciences employer, Takeda keeps reinventing itself

Takeda is doubling down on research and development in the Boston area with a host of new drugs in development for rare diseases, cancer, dengue and Covid-19.

Better Healthcare AI Stock: Moderna vs. Doximity

The AI in healthcare market is expected to top $100 billion by the end of the decade, and some companies are already leveraging this technology to advance their work. Two great examples are Moderna (NASDAQ: MRNA) and Doximity (NYSE: DOCS). Moderna isn't a novice when it comes to AI.

3 Nasdaq 100 Stocks That Are Surefire Buys in June

These phenomenal businesses have the tools and intangibles to make patient shareholders a lot richer.

The Zacks Analyst Blog Highlights NVIDIA, Bristol-Myers Squibb, ICICI Bank, Palo Alto and Walgreens Boots Alliance

NVIDIA, Bristol-Myers Squibb, ICICI Bank, Palo Alto and Walgreens Boots Alliance are included in this Analyst Blog.

Does The Market Have A Low Tolerance For Haleon plc's (LON:HLN) Mixed Fundamentals?

With its stock down 8.9% over the past month, it is easy to disregard Haleon (LON:HLN). We, however decided to study...

Bristol Myers Squibb (BMY) Gains But Lags Market: What You Should Know

Bristol Myers Squibb (BMY) closed the most recent trading day at $64.68, moving +0.37% from the previous trading session.

• 
  Paccar (PCAR) Outpaces Stock Market Gains: What You Should Know

  Zacks
• 
  3M (MMM) Outpaces Stock Market Gains: What You Should Know

  Zacks

Medicare Plans to Cover Alzheimer’s Drugs

Medicare plans to widen coverage of Alzheimer’s drugs that could win full approval as soon as this summer. The Centers for Medicare and Medicaid Services on Thursday said it would cover Biogen and Eisai treatment Leqembi if the drug wins full approval and patients and doctors contribute to a registry that collects evidence on how the medication works. Most Alzheimer’s patients in the U.S. are Medicare enrollees.

Is Pfizer Stock A Buy As It Leaps Into The Red-Hot Weight-Loss Race?

Is Pfizer stock a buy after the company unveiled promising weight-loss results for its diabetes pill? Is PFE stock a buy or a sell right now?

Dow Jones Today: Debt Vote Drives Index Higher

The Dow Jones Industrial Average moved higher by more than 0.5%, or 153 points, as investors celebrated the House of Representatives passage of the debt-ceiling bill, which now goes to the Senate.

Top Analyst Reports for NVIDIA, Bristol-Myers Squibb & ICICI Bank

Today's Research Daily features new research reports on 16 major stocks, including NVIDIA Corporation (NVDA), Bristol-Myers Squibb Company (BMY) and ICICI Bank Limited (IBN).

J&J secures dismissal of whistleblower case over misuse of confidential info

A federal appeals court, in a decision unsealed Wednesday, upheld the dismissal of a whistleblower lawsuit against Johnson & Johnson as a sanction for the plaintiffs' misuse of confidential records they obtained through related litigation. The lawsuit, which accused J&J's DePuy Orthopaedics unit of defrauding the federal government by marketing defective hip implants, was dismissed in December 2021. J&J has denied wrongdoing.

Biogen Hits Buy Zone On A Fresh Win For Its Alzheimer's Treatment; Eli Lilly, Eisai Shares Jump

Biogen stock jumped into a buy zone Thursday after Medicare officials said they would pay for some Alzheimer's treatments.

Biohaven, A Top 2% Stock, Exits 'Stealth Mode' And Hits A Record High

Biohaven is coming "out of stealth mode," an analyst said Thursday as BHVN stock climbed for a fourth consecutive day.